QEDDI is a business unit of UniQuest - the main commercialisation company of The University of Queensland. The QEDDI team form part of and are supported by UniQuest's Intellectual Property Commercialisation group and report through its management structure.
Dr Andrew Harvey
Dr Harvey heads the Queensland Emory Drug Discovery Initiative as a Senior Director at UniQuest. Prior to joining UniQuest, Dr Harvey was the Vice President of Drug Discovery at Bionomics Limited (Adelaide, Australia), a publicly-listed discovery and development company working across oncology, neuroscience and inflammation. In this role, he was responsible for leading chemistry and IP in programs ranging from hit identification to phase II clinical development, including two programs partnered with Merck & Co. While at Bionomics, Dr Harvey worked closely with the Cancer Therapeutics Cooperative Research Centre (CTx) as an industry partner and a member of the CTx operations group. Previously, Dr Harvey was an NHMRC Industry Fellow at the Walter and Eliza Hall Institute (Melbourne, Australia), where his research focused on autoimmune disease. He obtained his PhD in biological chemistry at the University of Canterbury (Christchurch, New Zealand).
Dr Terrie-Anne Cock
Dr Cock has worked across the pharmaceutical industry from discovery research to commercialisation. As Head of in vivo pharmacology and drug metabolism and pharmacokinetics (DMPK) for Prosidion (OSI Pharmaceutical; Oxford UK) Dr Cock developed first-in-class small molecules from discovery to phase II clinical development programs for diabetes and obesity treatments. At Pharmaxis (Sydney, Australia) and GlaxoSmithKline R&D (Ware, UK) she ensured new drugs had appropriate preclinical safety and DMPK packages to support all phases of clinical development in disease areas including oncology, inflammatory, respiratory, metabolic, cardiovascular, gastrointestinal, and neurobiological. Most recently she was Director of Translational Research at Benitec Biopharma (Sydney, Australia) developing DNA-directed RNA interference (ddRNAi) for gene therapy in cancer, ocular and infectious disease. Dr Cock obtained her PhD in Medicine at the Garvan Institute of Medical Research and UNSW.
Dr Brian Dymock
Dr Dymock leads the medicinal chemistry group working on small molecule preclinical drug discovery. Previously, he worked in discovery research and development in large pharmaceutical companies, biotech and academia. He was Associate Professor in Medicinal Chemistry at National University of Singapore; Head of Chemistry for S*BIO Pte Ltd in Singapore, where his team was responsible for the discovery of Pacritinib, Pracinostat, TG02, VS-5584 and two other clinical candidates; led the chemistry team at Vernalis which discovered Luminespib in collaboration with the Institute of Cancer Research; was a Department Manager at Evotec and a Team Leader at Roche UK. He earned his PhD in organic chemistry from the University of Glasgow.